Bojan Vujkovac
Slovenj Gradec, Slovenia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
A non-coding signature in SHROOM3 is associated with kidney disease progression in Fabry disease.
Journal: Molecular genetics and metabolism
Published: September 26, 2025
Identification of genetic variants associated with Fabry nephropathy progression using whole-exome sequencing.
Journal: Molecular genetics and metabolism
Published: March 19, 2025
Telomere Length, Oxidative Stress, and Kidney Damage Biomarkers in Fabry Nephropathy.
Journal: Cells
Published: January 09, 2025
Dynamics of Leukocyte Telomere Length in Patients with Fabry Disease.
Journal: Biomedicines
Published: July 01, 2024
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Journal: Journal of medical genetics
Published: June 02, 2023
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.
Journal: Orphanet journal of rare diseases
Published: January 19, 2023
Urinary-derived extracellular vesicles reveal a distinct microRNA signature associated with the development and progression of Fabry nephropathy.
Journal: Frontiers in medicine
Published: January 16, 2023
Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease.
Journal: Journal of clinical medicine
Published: June 30, 2022
An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease.
Journal: Molecular genetics and metabolism
Published: June 13, 2022
Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
Journal: Orphanet journal of rare diseases
Published: September 24, 2021
Last Updated: 09/26/2026